Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
Erdheim-Chester Disease 5K is Sept. 9 - Mason City Globe Gazette

Erdheim-Chester Disease 5K is Sept. 9
Mason City Globe Gazette
Erdheim-Chester Disease is a life-threatening condition that has no known cause. Symptoms can vary depending on the affected organs and is usually diagnosed through biopsy and body scans. Bob Rodgers is one of three people in Iowa to have the ...


Sunday, August 23, 2015 7:45:38 PM

Histology, Tumor Markers Both Critical in Personalizing Cancer Treatment ... - GenomeWeb

Histology, Tumor Markers Both Critical in Personalizing Cancer Treatment ...
GenomeWeb
The "baskets" included patients with non-small-cell lung cancer, cholangiocarcinoma, Erdheim-Chester disease, Langerhans cell histiocytosis, anaplastic thyroid cancer, multiple myeloma, and other tumor types. Previous case studies had offered hints ...


Thursday, August 27, 2015 3:48:20 PM

Remarkable breakthroughs for ultra-rare disease thanks to DeRidder group - KPLC-TV

Remarkable breakthroughs for ultra-rare disease thanks to DeRidder group
KPLC-TV
Every day in the DeRidder office for Kathy Brewer and Jessica Corkran with the Erdheim-Chester Disease Global Alliance is full of brainstorming sessions, note taking, doctor calls, and international e-mails with people around the world affected by this ...


Thursday, August 06, 2015 1:49:23 PM

'Basket' Cancer Trial Hints at Promise - MedPage Today

'Basket' Cancer Trial Hints at Promise
MedPage Today
... for melanoma demonstrated modest antitumor activity in nonmelanoma cancers that sporadically express the BRAF V600 mutation, the best results being in non-small cell lung cancer (NSCLC), Erdheim-Chester disease, and Langerhans-cell histiocytosis, ...


Wednesday, August 26, 2015 2:31:19 PM

Cancer Researchers Publish Landmark "Basket Study" - Drug Discovery & Development

Drug Discovery & Development

Cancer Researchers Publish Landmark "Basket Study"
Drug Discovery & Development
People with lung, colorectal, and ovarian cancers were among those included in the study as well as people with rare diseases, such as Erdheim-Chester disease. Until this point, the efficacy of vemurafenib in nonmelanoma cancers has remained unexplored ...
New Kind of Cancer Study Finds New Targets for Tailored Treatments
Basket Trial Finds New Tumor Types That Respond to BRAF Inhibition
Vemurafenib shows promise for BRAFV600 -mutated nonmelanoma cancers


Thursday, August 20, 2015 1:56:06 PM

Mother With Stage-Four Cancer Finds Hope in New Treatment Called a 'Basket Trial' - ABC News

ABC News

Mother With Stage-Four Cancer Finds Hope in New Treatment Called a 'Basket Trial'
ABC News
Patients with a rare cancer called Erdheim-Chester disease spent a median 5.9 months on the drug before the cancer progressed and 43 percent of patients responded to the treatment. However, study authors acknowledged the findings were preliminary.


Friday, August 21, 2015 5:14:41 PM

The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure - Washington Post

The ultra-rare Erdheim-Chester disease: Turning grief into a campaign for a cure
Washington Post
The cause was Erdheim-Chester disease (ECD), one of 7,000 diseases tracked by the nonprofit National Organization for Rare Disorders. The National Institutes of Health and the Food and Drug Administration call such ailments “orphan” diseases because ...


Monday, November 17, 2014 4:47:28 PM

Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations - Pharmacy Today, American Pharmacists Association, pharmacist.com

Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
Pharmacy Today, American Pharmacists Association, pharmacist.com
The response rate in the cohort with Erdheim–Chester disease or Langerhans'-cell histiocytosis was 43%, and no patients had disease progression during treatment. The most common adverse events among individuals receiving vemurafenib monotherapy ...


Thursday, August 20, 2015 9:05:35 AM

Precision medicine approach effective in lung cancer - BioNews

Precision medicine approach effective in lung cancer
BioNews
The strategy also showed efficacy in two rare conditions involving white blood cell overproliferation, Erdheim-Chester disease and Langherhans cell histiocytosis, where the response rate was 43 percent. And, despite a median treatment duration of 5.9 ...
Cancer study finds new targets for tailored treatments


Monday, August 24, 2015 12:03:36 PM

Patient Tumor Mutations and Drug Responses - Updated News

Updated News

Patient Tumor Mutations and Drug Responses
Updated News
People with lung, colorectal, and ovarian cancers were among those included in the study as well as people with rare diseases, such as Erdheim-Chester disease. Until this point, the efficacy of vemurafenib in nonmelanoma cancers has remained unexplored ...


Sunday, August 23, 2015 6:24:11 PM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Tax ID: 22-2827069 | Privacy | DisclaimerContact Us | Site Map
Follow Me on Pinterest